Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ethan Bernard Ludmir"'
Autor:
Alex Koong, Ulysses Grant Gardner, Jason Burton, Caleb Stewart, Petria Thompson, Clifton David Fuller, Ethan Bernard Ludmir, Michael Kevin Rooney
Publikováno v:
JMIR Formative Research, Vol 7, p e44633 (2023)
BackgroundOpen access (OA) publishing represents an exciting opportunity to facilitate the dissemination of scientific information to global audiences. However, OA publishing is often associated with significant article processing charges (APCs) for
Externí odkaz:
https://doaj.org/article/a7af86cd1df14d06999e78fc85a96836
Autor:
Alex Koong, Ulysses Grant Gardner, Jason Burton, Caleb Stewart, Petria Thompson, Clifton David Fuller, Ethan Bernard Ludmir, Michael Kevin Rooney
BACKGROUND Open access (OA) publishing represents an exciting opportunity to facilitate the dissemination of scientific information to global audiences. However, OA publishing is often associated with significant article processing charges (APCs) for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7669fa546857a150da18c5942a6fec72
https://doi.org/10.2196/preprints.44633
https://doi.org/10.2196/preprints.44633
Autor:
Gohar Shahwar Manzar, Brian Sandeep De, Chike Osita Abana, Sunyoung S. Lee, Milind Javle, Ahmed O. Kaseb, Jean-Nicolas Vauthey, Hop Sanderson Tran Cao, Albert C. Koong, Grace Li Smith, Cullen M. Taniguchi, Emma Brey Holliday, Prajnan Das, Eugene Jon Koay, Ethan Bernard Ludmir
Publikováno v:
Cancers; Volume 14; Issue 8; Pages: 1901
Atezolizumab plus bevacizumab has become frontline therapy for unresectable HCC. The compatibility of atezolizumab/bevacizumab with liver-directed RT has not been reported. Methods: HCC patients treated with liver-directed RT and atezolizumab/bevaciz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b1c40f6102d2ec875a4c8154615b8c